School of Medicine


Showing 201-250 of 629 Results

  • Gary Glover

    Gary Glover

    Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Psychology and of Electrical Engineering

    Current Research and Scholarly InterestsMy present research is devoted to the advancement of functional magnetic resonance imaging sciences for applications in basic understanding of the brain in health and disease. We collaborate closely with departmental clinicians and with others in the school of medicine, humanities, and the engineering sciences.

  • Jeremy Goldhaber-Fiebert

    Jeremy Goldhaber-Fiebert

    Professor of Health Policy

    BioJeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy and a Core Faculty Member in the Centers for Health Policy and Primary Care and Outcomes Research. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011 and Secretary/Treasurer in 2021.

    Past and current research topics:

    - Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.

    -Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.

    - Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.

    - Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.

    - Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity.

  • Steven Goodman

    Steven Goodman

    Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy

    Current Research and Scholarly InterestsI am interested in issues relating to the representation and measurement of evidence in medical research, and determinants of the truth of medical findings, using a Bayesian framework. I also do work in evidence synthesis, comparative effectiveness research, and the ethics of clinical research.

  • Jason Gotlib

    Jason Gotlib

    Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
    --Myelodysplastic syndromes (MDS)
    --Chronic myelogenous leukemia (CML)
    --Acute myelogenous leukemia (AML)
    --Myeloproliferative disorders (MPDs) including:
    Hypereosinophilic syndrome
    Systemic mastocytosis
    BCR-ABL-negative MPDs

  • Or Gozani

    Or Gozani

    Dr. Morris Herzstein Professor

    Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.

  • Dita Gratzinger

    Dita Gratzinger

    Professor of Pathology

    Current Research and Scholarly InterestsI have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.

  • Edward Graves

    Edward Graves

    Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)

    Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.

  • Nathanael S. Gray

    Nathanael S. Gray

    Krishnan-Shah Family Professor

    BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
    Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
    In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
    In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
    These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.

  • Henry T. (Hank) Greely

    Henry T. (Hank) Greely

    Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics

    Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.

  • Harry B Greenberg

    Harry B Greenberg

    Joseph D. Grant Professor in the School of Medicine, Emeritus

    Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.

  • Peter Greenberg

    Peter Greenberg

    Professor of Medicine (Hematology), Emeritus

    Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.

  • William Greenleaf

    William Greenleaf

    Professor of Genetics

    Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.

  • Xuejun Gu

    Xuejun Gu

    Associate Professor of Radiation Oncology (Medical Physics)

    Current Research and Scholarly InterestsArtificial intelligence in medicine
    Medical imaging and image anlysis
    Treatment planning and clinical decision-making
    FLASH radiobiology study ;

  • James Hallenbeck, MD

    James Hallenbeck, MD

    Associate Professor of Medicine (Primary Care and Population Health) at the Palo Alto Veterans Affairs Health Care System, Emeritus

    Current Research and Scholarly InterestsResearch in hospice and palliative care with emphases on physician education, cultural aspects of end-of-life care, and healthcare system issues.

  • Bonnie Halpern-Felsher

    Bonnie Halpern-Felsher

    Marron and Mary Elizabeth Kendrick Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health and of Psychiatry and Behavioral Sciences (Child and Adolescent Psychiatry)

    Current Research and Scholarly InterestsResearch focuses on developmental, cognitive and psychosocial factors involved in adolescents’ and young adults’ health-related decision-making, perceptions of risk and vulnerability, health communication and risk behavior. My research has focused on understanding and reducing health risk behaviors such as tobacco use, alcohol and marijuana use, risky driving, and risky sexual behavior.

  • Summer Han

    Summer Han

    Associate Professor (Research) of Neurosurgery, of Medicine (Biomedical Informatics) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsMy current research focuses on understanding the genetic and environmental etiology of complex disease and developing and evaluating efficient screening strategies based on etiological understanding. The areas of my research interests include statistical genetics, molecular epidemiology, cancer screening, health policy modeling, and risk prediction modeling. I have developed various statistical methods to analyze high-dimensional data to identify genetic and environmental risk factors and their interactions for complex disease.

  • Philip C. Hanawalt

    Philip C. Hanawalt

    Dr. Morris Herzstein Professor in Biology, Emeritus

    Current Research and Scholarly InterestsMy current interest includes two principal areas:

    1. The molecular basis for diseases in which the pathway of transcription-coupled DNA repair is defective, including Cockyne syndrome (CS) and UV-sensitive syndrome (UVSS). Patients are severely sensitive to sunlight but get no cancers. See Hanawalt & Spivak, 2008, for review.

    2. Transcription arrest by guanine-rich DNA sequences and non-canonical secondary structures. Transcription collisions with replication forks.

  • Sigurdis Haraldsdottir

    Sigurdis Haraldsdottir

    Member, Stanford Cancer Institute

    BioDr. Sigurdis Haraldsdottir, M.D., Ph.D. is an Assistant Professor of Medicine at Stanford University School of Medicine. She received her medical degree and master's degree in medical sciences from the University of Iceland. She did her Internal Medicine training at Boston University Medical Center and training in Medical Oncology at the Ohio State University, before joining the faculty at Stanford. Her clinical and research focus is in gastrointestinal malignancies with a focus on mismatch repair deficient cancers, particularly colorectal cancer. She is conducting population-based research on Lynch syndrome - an inherited cancer syndrome, and recently completed a nation-wide study on Lynch syndrome in Iceland. She received her Ph.D. in Medical Sciences in 2017 from the University of Iceland. Her interests also focus on investigating colorectal cancer genomics, and their effect on outcomes and treatment implications.

  • Pehr Harbury

    Pehr Harbury

    Associate Professor of Biochemistry

    Current Research and Scholarly InterestsScientific breakthroughs often come on the heels of technological advances; advances that expose hidden truths of nature, and provide tools for engineering the world around us. Examples include the telescope (heliocentrism), the Michelson interferometer (relativity) and recombinant DNA (molecular evolution). Our lab explores innovative experimental approaches to problems in molecular biochemistry, focusing on technologies with the potential for broad impact.

  • Brian A. Hargreaves

    Brian A. Hargreaves

    Professor of Radiology (Radiological Sciences Laboratory) and, by courtesy, of Electrical Engineering and of Bioengineering

    Current Research and Scholarly InterestsI am interested in magnetic resonance imaging (MRI) applications and augmented reality applications in medicine. These include abdominal, breast and musculoskeletal imaging, which require development of faster, quantitative, and more efficient MRI methods that provide improved diagnostic contrast compared with current methods. My work includes novel excitation schemes, efficient imaging methods and reconstruction tools and augmented reality in medicine.

  • William Haskell

    William Haskell

    Professor (Research) of Medicine, Emeritus

    Current Research and Scholarly InterestsMy major research interests and activities over the next several years will focus on the development and evaluation of the objective measurement of physical activity in free-living populations using a variety of sensing devices and mobile phones for data collection and processing. Also, I will continue to direct the Stanford Heart Network with the major mission being to assist community-based CVD prevention/treatment programs implement more effective heart attack and stroke prevention programs.

  • Trevor Hastie

    Trevor Hastie

    John A. Overdeck Professor, Professor of Statistics and of Biomedical Data Sciences

    Current Research and Scholarly InterestsFlexible statistical modeling for prediction and representation of data arising in biology, medicine, science or industry. Statistical and machine learning tools have gained importance over the years. Part of Hastie's work has been to bridge the gap between traditional statistical methodology and the achievements made in machine learning.

  • Melanie Hayden Gephart

    Melanie Hayden Gephart

    Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences

    BioI am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including gliomas, brain metastases, meningiomas, and schwannomas. I direct the Stanford Brain Tumor Center and the Stanford Brain Metastasis Consortium, collaborative unions of physicians and scientists looking to improve our understanding and treatment of brain tumors. My laboratory seeks greater understanding of the mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We study how rare cancer cell populations survive and migrate in the brain, inadvertently supported by native brain cells. We develop novel cerebrospinal fluid-based biomarkers to track brain cancer treatment response, relapse, and neurotoxicity. Our bedside-to-bench-to-bedside research model builds on a foundation of generously donated patient samples, where we test mechanisms of brain cancer growth, develop novel pre-clinical models that reliably recapitulate the human disease, and facilitate clinical trials of new treatments for patients with brain cancer.

    www.GephartLab.com
    www.GBMseq.org
    https://stan.md/BrainMets
    @HaydenGephartMD

  • Gregory M. Heestand, MD

    Gregory M. Heestand, MD

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.

    Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.

    Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read.

  • Stefan Heller

    Stefan Heller

    Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor of Otolaryngology - Head & Neck Surgery (OHNS)
    On Partial Leave from 09/01/2024 To 02/28/2025

    Current Research and Scholarly InterestsOur research focuses on the inner ear, from its earliest manifestation as one of the cranial placodes until it has developed into a mature and functioning organ. We are interested in how the sensory epithelia of the inner ear that harbor the sensory hair cells develop, how the cells mature, and how these epithelia respond to toxic insults. The overarching goal of this research is to find ways to regenerate lost sensory hair cells in mammals.

  • Lisa Henriksen

    Lisa Henriksen

    Associate Professor (Research) of Medicine (Stanford Prevention Research Center)
    Sr Research Engineer, Medicine - Stanford Prevention Research Center

    Current Research and Scholarly InterestsMy research aims to improve our understanding of the health risks associated with exposure to tobacco marketing and provide a scientific rationale for new policies to reduce it. I also study use of media to promote and discourage adolescent tobacco use, and the impact of tobacco advertising on urge and craving to smoke.

  • Robert Herfkens

    Robert Herfkens

    Professor of Radiology (Cardiovascular Imaging), Emeritus

    Current Research and Scholarly InterestsImaging of cardiovascular diseases with CT, magnetic resonance imaging and spectroscopy

  • Tina Hernandez-Boussard

    Tina Hernandez-Boussard

    Professor of Medicine (Biomedical Informatics), of Biomedical Data Science, of Surgery and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsMy background and expertise is in the field of computational biology, with concentration in health services research. A key focus of my research is to apply novel methods and tools to large clinical datasets for hypothesis generation, comparative effectiveness research, and the evaluation of quality healthcare delivery. My research involves managing and manipulating big data, which range from administrative claims data to electronic health records, and applying novel biostatistical techniques to innovatively assess clinical and policy related research questions at the population level. This research enables us to create formal, statistically rigid, evaluations of healthcare data using unique combinations of large datasets.

  • Rogelio A. Hernández-López

    Rogelio A. Hernández-López

    Assistant Professor of Bioengineering and of Genetics

    Current Research and Scholarly InterestsOur group works at the interface of mechanistic, synthetic, and systems biology to understand and program cellular recognition, communication, and organization. We are currently interested in engineering biomedical relevant cellular behaviors for cancer immunotherapy.

  • Daniel Herschlag

    Daniel Herschlag

    Professor of Biochemistry and, by courtesy, of Chemical Engineering

    Current Research and Scholarly InterestsOur research is aimed at understanding the chemical and physical behavior underlying biological macromolecules and systems, as these behaviors define the capabilities and limitations of biology. Toward this end we study folding and catalysis by RNA, as well as catalysis by protein enzymes.

  • Mark Hlatky, MD

    Mark Hlatky, MD

    Professor of Health Policy, of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsMy main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.

  • Andrew R. Hoffman

    Andrew R. Hoffman

    Professor of Medicine (Endocrinology), Emeritus

    Current Research and Scholarly InterestsMechanism of genomic imprinting of insulin like growth factor-2 and other genes.Long range chromatin interactions Role of histone modifications and DNA methylation in gene expression.

  • Lawrence "Rusty" Hofmann, MD

    Lawrence "Rusty" Hofmann, MD

    Professor of Radiology (Interventional Radiology)

    BioDr. Lawrence “Rusty” Hofmann is an actively practicing physician and Professor of Interventional Radiology at Stanford School of Medicine, as well as the Chief of Industry Partnerships for Stanford Healthcare, Medical Director of Cardiac and Interventional Services, and the Medical Director of Digital Health at Stanford Medicine. He served as Chief of Interventional Radiology at Stanford for nearly two decades. He is the Co-Founder of Grand Rounds, Inc, rebranded as Included Health. He has devoted his career to providing state-of-the-art care to patients at either Johns Hopkins, where he practiced for 10 years, or Stanford, where he practiced for 15 years. He has published over 100 scientific articles on minimally invasive treatment of blood clots (DVT) and cancer. He has always had in interest in innovation. He holds 2 patents, has worked as a consultant for numerous medical device companies, both start-ups and large companies and is currently the Global-Principal Investigator for the first clinical trial testing a venous stent. He has invented and brought a number of devices from napkin stage to world-wide use. He has active digital health research projects at the intersection of artificial intelligence and clinical care, including telemedicine and deep venous thrombosis.

  • Chris Holsinger, MD, FACS

    Chris Holsinger, MD, FACS

    Professor of Otolaryngology - Head & Neck Surgery (OHNS)
    Master of Liberal Arts Student, admitted Autumn 2024

    Current Research and Scholarly InterestsDr. Holsinger’s surgical practice focuses on the surgical management of benign and malignant diseases of the thyroid, parathyroid and head and neck.

    His areas of clinical interest include endoscopic head and neck surgery, including robotic thyroidectomy, transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery, supracricoid partial laryngectomy.

  • Jody Elizabeth Hooper

    Jody Elizabeth Hooper

    Associate Professor of Pathology

    Current Research and Scholarly InterestsI am the Director of the Research Autopsy Collaboration at Stanford (RACS) to collect organs and tissues from decedent donors for cancer and disease research. https://med.stanford.edu/racs
    I have a number of research interests associated with my autopsy work, including how the time interval between death and collection (the PMI) affects the condition and research viability of the collected tissue, how valuable blood and tissue cultures behave after death, and how autopsy results affect clinical practice in an established information loop. I have projects exploring physician and family attitudes towards autopsy and the utilization of rapid autopsy tissue in characterizing cancer evolution from genetic and immunologic standpoints.

  • Richard Hoppe

    Richard Hoppe

    Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology

    Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.